Goldman Sachs Group Inc Cor Medix Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Cor Medix Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 135,388 shares of CRMD stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

135,388

Previous 70,790 91.25%

Holding current value

$1.11 Million

Previous $306,000 257.19%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.64 - $8.23 $235,136 - $531,641	64,598 Added 91.25%	135,388 $1.09 Million
Q2 2024 Aug 13, 2024	BUY	$4.08 - $6.39 $118,634 - $185,802	29,077 Added 69.71%	70,790 $306,000
Q1 2024 May 15, 2024	BUY	$2.94 - $4.24 $13,709 - $19,771	4,663 Added 12.59%	41,713 $176,000
Q4 2023 Feb 13, 2024	SELL	$3.0 - $4.01 $17,619 - $23,550	-5,873 Reduced 13.68%	37,050 $139,000
Q3 2023 May 14, 2024	BUY	$3.6 - $4.46 $21,142 - $26,193	5,873 Added 15.85%	42,923 $158,000
Q3 2023 Nov 14, 2023	BUY	$3.6 - $4.46 $114,991 - $142,461	31,942 Added 290.88%	42,923 $158,000
Q2 2023 May 14, 2024	SELL	$3.94 - $5.8 $59,935 - $88,229	-15,212 Reduced 58.08%	10,981 $43,000
Q2 2023 Aug 14, 2023	BUY	$3.94 - $5.8 $43,265 - $63,689	10,981 New	10,981 $43,000
Q2 2022 May 14, 2024	SELL	$2.73 - $5.61 $29,639 - $60,907	-10,857 Reduced 29.3%	26,193 $105,000
Q2 2022 Aug 15, 2022	SELL	$2.73 - $5.61 $53,095 - $109,108	-19,449 Reduced 42.61%	26,193 $105,000
Q1 2022 May 16, 2022	SELL	$3.83 - $6.24 $83,176 - $135,514	-21,717 Reduced 32.24%	45,642 $250,000
Q4 2021 Feb 14, 2022	BUY	$4.47 - $5.56 $159,806 - $198,775	35,751 Added 113.11%	67,359 $306,000
Q3 2021 Nov 10, 2021	BUY	$4.46 - $7.11 $140,971 - $224,732	31,608 New	31,608 $147,000

Others Institutions Holding CRMD

# of Institutions

105

Shares Held

17.4M

Call Options Held

134K

Put Options Held

441K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $339M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Cor Medix Inc. Transaction History